Zynerba Pharmaceuticals (Nasdaq:ZYNE) is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments. It has a market cap of $83.3 million, and is not profitable.. Guest Devin Shutte from The Robert Group and resident expert Paul Theron from Vestact decide whether Zynerba Pharmaceuticals is hot or not.